Retatrutide: Clinical Guide for Prescribing Practices
Retatrutide is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trials demonstrated unprecedented weight loss of up to 24% body weight at 48 weeks. It represents the next generation of incretin-based therapies and is currently in late-stage development.
Also Known As
How Retatrutide Works
Retatrutide activates three distinct receptors: GLP-1 (appetite suppression, gastric slowing), GIP (insulin sensitivity, adipose metabolism), and glucagon (hepatic lipid oxidation, energy expenditure) [1]. The glucagon receptor component differentiates it from dual agonists by increasing thermogenesis and promoting hepatic fat mobilization. This triple mechanism produces the most complete metabolic effect of any incretin-based therapy currently in development [3].
Clinical Evidence
The phase 2 trial published in NEJM (2023) demonstrated dose-dependent weight loss of up to 24.2% at 48 weeks with retatrutide 12mg weekly, exceeding results seen with both semaglutide and tirzepatide at equivalent timepoints [1]. Participants also showed significant reductions in hepatic steatosis (up to 86% relative reduction in liver fat). Phase 3 trials (TRIUMPH program) are underway with results expected in 2025-2026 [2]. A separate phase 2 study in patients with type 2 diabetes confirmed glycemic benefits alongside weight reduction [3].
Clinical Uses
Patient Selection and Screening
Potential candidates include patients with severe obesity (BMI 35+) seeking maximum weight loss, those who have plateaued on GLP-1 or dual-agonist therapy, and patients with concurrent NAFLD/NASH who may benefit from the hepatic effects [1]. Given limited long-term safety data, reserve for patients who understand the investigational nature [2]. Screen for the same contraindications as other incretin therapies. Patients with poorly controlled diabetes should be monitored closely due to the glucagon component's effect on hepatic glucose output [3].
Dosing and Administration
Phase 2 protocols titrated from 1mg weekly to maximum 12mg weekly over 24 weeks [1]. Dose escalation intervals were 4 weeks. Most clinical benefit observed at 8mg and 12mg dose levels. As this compound is not yet FDA approved, dosing protocols are based on published trial data and should be considered investigational [2]. Individualize based on tolerance and clinical response; the glucagon component warrants careful monitoring of blood glucose [3].
Route: Subcutaneous injection
Protocol notes: Weekly subcutaneous injection with dose titration. Clinical trial protocols used starting doses of 1mg with titration to 12mg over several months.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Retatrutide represents a forward-looking opportunity for practices to position as early adopters of next-generation metabolic therapies [1]. Current compounded availability is limited, but practices offering retatrutide can attract patients seeking cutting-edge options beyond standard GLP-1 therapy. Pricing typically exceeds tirzepatide due to novelty and limited supply, with patient spend in the $500-800 monthly range where available.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Retatrutide through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What makes retatrutide different from tirzepatide?
Is retatrutide available for prescribing now?
References
Related Peptides in Weight Loss & Metabolic
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Retatrutide Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Retatrutide Through Karpa